1. ALLA AKTIER
  2. NYHETER
  3. SIMRIS ALG

Simris Alg

Nyheter Simris Alg Nyheter alla bolag
eToro Trading Platform Advertisement
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Simris Group CEO, Julian Read, answers questions from Finwire regarding company strategy and its ongoing Rights Issue

Julian Read, CEO for Simris Group AB clarifies the strategic focus for the Company, its business model for its Antibody Drug Conjugate (ADC) products and how funds from the ongoing capital raising will be prioritised during an interview with Finwire.

The interview can be viewed at www.youtube.com/watch?v=ogonDAE4UuY&t=12s.

Contact Details:
Julian Read
CEO Simris Group AB
Email: ir@simris.com
Mobile: +46767888212
www.simrisgroup.com

About Simris Group AB (PUBL):
Simris Group is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds. 
Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments
Simris Group CEO, Julian Read, answers questions from Finwire regarding company strategy and its ongoing Rights Issue

Datum 2023-08-08, kl 14:15
Källa MFN
Bifogade filer
Simris Group CEO, Julian Read, answers questions from Finwire regarding company strategy and its ongoing Rights Issue